Received Sep 15, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| RAB | RABIES (IMOVAX) | SANOFI PASTEUR | 1 | — | OT |
received the first imovax pre-exposure dose but missed the second scheduled dose with no reported adverse event; Initial information received on 10-Sep-2025 regarding an unsolicited valid non-serious case received from a pharmacist. This case involves an unknown age and unknown gender patient who received the first RABIES (HDC) VACCINE [IMOVAX RABIES] pre-exposure dose but missed the second scheduled dose with no reported adverse event. The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided. On 22-Aug-2025, the patient received a Dose 1 of suspect RABIES (HDC) Vaccine Powder and solvent for suspension for injection (lot number, strength, dose and expiry not reported) via unknown route in unknown administration site as pre-exposure prophylaxis. Information regarding batch number and expiration date corresponding to the one at time of event occurrence was requested. The patient was scheduled for administration of second dose on 29-Aug-2025, but missed the same with no reported adverse event (Routine immunisation schedule not administered) (Latency: 7 days) from 1st dose of suspect. Reportedly, As of 10-SEP-2025, the pharmacy already has "the vaccine in stock" and informed the patient they could come and receive it. The patient then expressed concern about needing to restart the dosage schedule. The pharmacist wanted to know whether the patient has to "restart the entire series or can they just get it as soon as possible. Pharmacist provided the lot number and expiration date of the second IMOVAX dose scheduled to be given to the patient as Lot: Y1A86P1, Expiry: 28-Feb-2025. Action taken: not applicable. This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.